“…However, the potential clinical utility of several of the N-terminal inhibitors as anticancer drugs has been dampened significantly due to concerns about their adverse hepatotoxic effects (Egorin et al, 1998) and tendency to induce expression of cytoprotective Hsp90 and Hsp70 proteins (Chiosis et al, 2003;Whitesell et al, 2003;Powers and Workman, 2007;Schmitt et al, 2007). More recently, the observation was made that Hsp90 contains a previously unrecognized C-terminal ATP-binding domain (Marcu et al, 2000a,b), which has led several groups to pursue the development of specific C-terminal Hsp90 inhibitors as potential anticancer drug modalities (Burlison et al, 2006Le Bras et al, 2007;Donnelly et al, 2008;Radanyi et al, 2009). Both N-terminal and C-terminal Hsp90 inhibitors can exert an antiproliferative response, in some instances, by stimulating apoptosis (Isaacs et al, 2003;Georgakis and Younes, 2005;Whitesell and Lindquist, 2005), although the underlying mechanisms are not well understood.…”